April 19, 2017
April 19, 2017 —
…survive tongue cancer but after participating in an immunotherapy clinical trial at Moores Cancer Center at UC San Diego Health, he was declared cancer-free in July 2016. To give back, Rockett is now asking concert-goers to join him in supporting immunotherapy at Moores Cancer Center.
March 28, 2019
March 28, 2019 —
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, report on a novel four-year, randomized clinical trial evaluating different home-based methods to assess cognitive function and decline in participants over the age of 75.
January 23, 2012
January 23, 2012 —
…care to patients through expert diagnosis, novel treatments and clinical trials.
March 17, 2016
March 17, 2016 —
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine approved yesterday a $6.3 million grant to a research team from the University of California, San Diego School of Medicine and University of California, Davis to pursue a novel human embryonic stem cell-based therapy to rescue and restore…
June 1, 2018
June 1, 2018 —
…a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
April 3, 2018
April 3, 2018 —
The Lewy Body Dementia Association (LBDA), announced today that UC San Diego Health has been named a LBDA Research Centers of Excellence (RCOE), a partnership of 24 pre-eminent academic medical research centers across the United States. LBDA is a leading advocacy group dedicated to raising awareness and advancing research and…
February 23, 2016
February 23, 2016 —
…UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells – one of the immune system’s primary weapons – to treat three different types of blood cancer that often defy existing therapies.
November 30, 2017
November 30, 2017 —
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University of California San Diego School of Medicine researchers identified a strategy that pinpoints a genetically…
April 1, 2019
April 1, 2019 —
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
June 25, 2015
June 25, 2015 —
Two of the nation’s leading physician-scientists in the search to better understand and treat Alzheimer’s disease – William Mobley, MD, PhD, and Michael Rafii, MD, PhD – have been named interim co-directors of the Alzheimer’s Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between…